Candriam Luxembourg S.C.A. purchased a new position in shares of Akcea Therapeutics, Inc. (NASDAQ:AKCA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 192,058 shares of the company’s stock, valued at approximately $5,314,000. Candriam Luxembourg S.C.A. owned 0.29% of Akcea Therapeutics at the end of the most recent quarter.
Separately, Strs Ohio purchased a new position in shares of Akcea Therapeutics during the 3rd quarter worth $118,000. Hedge funds and other institutional investors own 0.45% of the company’s stock.
Akcea Therapeutics, Inc. (AKCA) opened at $17.58 on Tuesday. Akcea Therapeutics, Inc. has a twelve month low of $8.10 and a twelve month high of $31.23.
A number of equities analysts recently commented on AKCA shares. Zacks Investment Research cut Akcea Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Wells Fargo & Company started coverage on Akcea Therapeutics in a report on Tuesday, August 8th. They set an “outperform” rating and a $27.00 target price for the company. Cowen and Company started coverage on Akcea Therapeutics in a report on Tuesday, August 8th. They set an “outperform” rating for the company. Stifel Nicolaus started coverage on Akcea Therapeutics in a report on Tuesday, August 8th. They set a “buy” rating and a $19.00 target price for the company. Finally, BMO Capital Markets started coverage on Akcea Therapeutics in a report on Tuesday, August 8th. They set an “outperform” rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Akcea Therapeutics has an average rating of “Buy” and a consensus price target of $24.00.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.thestockobserver.com/2017/11/14/candriam-luxembourg-s-c-a-purchases-new-holdings-in-akcea-therapeutics-inc-akca.html.
Akcea Therapeutics Profile
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Want to see what other hedge funds are holding AKCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akcea Therapeutics, Inc. (NASDAQ:AKCA).
Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.